Revelation Biosciences (REVB)
(Delayed Data from NSDQ)
$1.00 USD
-0.05 (-4.76%)
Updated Aug 9, 2024 03:59 PM ET
After-Market: $0.99 -0.01 (-1.00%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMRevelation Biosciences, Inc. (REVB) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$18.70 | $25.00 | $12.40 | 1,680.95% |
Price Target
Based on short-term price targets offered by two analysts, the average price target for Revelation Biosciences, Inc. comes to $18.70. The forecasts range from a low of $12.40 to a high of $25.00. The average price target represents an increase of 1% from the last closing price of $1.05.
Analyst Price Targets (2 )
Broker Rating
Only one brokerage firm provided a Strong Buy-equivalent recommendation for Revelation Biosciences, Inc. This translates to an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell). ABR is the calculated average of actual recommendations (Buy, Hold, Sell etc.) made by brokerage firms.
The current ABR compares to an ABR of 1.00 a month ago based on just one Strong Buy recommendation.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/REVB.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 1 | 1 | 1 | 1 | 1 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
5/13/2024 | Roth Capital Partners | Jonathan Aschoff | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.00 |
ABR (Last week) | 1.00 |
# of Recs in ABR | 1 |
Average Target Price | $18.70 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 75 of 253 |
Current Quarter EPS Est: | -2.09 |